Characterisation of TRAIL Receptor Signalling To Apoptosis in Pre-clinical Models of Breast Cancer
Year: 2011
Type: dissertation
Abstract: TNF-Related Apoptosis-Inducing Ligand (TRAIL) belongs to the TNF cytokine family\nand can signal to apoptosis by binding to either of two membrane-bound death\nreceptors, TRAIL-R1 or TRAIL-R2. Using ligands specific for TRAIL-R1 (R1L) or\nTRAIL-R2 (R2L), our laboratory has previously shown that combining a histone\ndeacetylase inhibitor with R1L, but not R2L, induces apoptosis in primary chronic\nlymphocytic leukaemia cells. The aim of this project was to extend the profiling of\nTRAIL-Receptor signalling to breast cancer, using breast cancer cell lines and\nimportantly primary breast tumours as model systems.\nA 3-dimensional explant culturing technique was employed to maintain the primary\ntumour architecture and mimic the breast tumour microenvironment. In addition,\ntumour-initiating cells from advanced metastatic breast cancer patients were also\ntested for their sensitivity to TRAIL. The results obtained from breast cancer cell lines,\nprimary mucinous carcinomas and advanced metastatic breast cancer cells suggest\nthat in breast cancer, TRAIL-R1 is the predominant functional TRAIL death receptor\nindependent of oestrogen receptor status. In contrast, invasive ductal/lobular\ncarcinomas (IDC/ILC) were resistant to TRAIL-induced apoptosis and required the\nbreast cancer chemotherapeutic, doxorubicin as a sensitising agent. Studies using the\nTRAIL-resistant cell line, T47D, demonstrated that doxorubicin sensitised tumour cells\nto TRAIL-induced apoptosis via enhanced TRAIL DISC formation. Importantly, in\nprimary tumour explants, the combination of doxorubicin and TRAIL signalled to\napoptosis exclusively in the tumour cells, but not in normal cells. Significantly, in four\nIDC/ILC tumours, doxorubicin sensitised breast tumour cells to R1L more efficiently\nthan R2L. Therefore, using R1L in combination with sub-lethal doses of\nchemotherapeutic agents could improve the benefit of conventional therapy whilst\nreducing drug-associated side-effects and potential TRAIL-mediated cell\nproliferation/survival in apoptosis-resistant tumour cells. My data suggest that using a\nTRAIL-R1-selective agonist with an appropriate sensitising agent (example,\ndoxorubicin), offers a promising therapeutic approach for treatment of breast cancer.
Author: Shambhavi Naik
Institution: University of Leicester
Language: English
Subfield: Molecular Biology
Domain: Life Sciences
Open Access status: green
OpenAlex ID: W29504459
